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Abstract: A highly viscous substance was prepared by evaporating an ethanol solution containing
two hydrophilic vitamins; vitamin C, and vitamin B6. The viscous substance and physical mixture of
the two vitamins were tested using a differential scanning calorimeter and an X-ray diffractometer.
The highly viscous substance was found to be a liquid crystal (LC) made of these two hydrophilic
vitamins. Determination by proton nuclear magnetic resonance measurement suggested that
intramolecular hydrogen bonding in vitamin B6 was eliminated by the LC formation. This LC
compound showed high solubility in 1,3-butanediol (almost 87%). Much higher skin permeation of
both vitamin C and B6 was also observed from the LC compound than that from the physical mixture.
The present LC compound containing vitamin C and vitamin B6 may be useful for pharmaceutical
and cosmeceutical applications.
Keywords: liquid crystal; vitamin C; vitamin B6; solubility; skin permeation
1. Introduction
In general, a salt composed of a strong acid and a weak base becomes a crystal (solid), whereas
some organic salts composed of a weak Lewis acid and a weak Lewis base become a liquid at room
temperature. These substances are called liquid electrolytes, ionic melts, ionic fluids, fused salts, liquid
salts, or ionic glasses to differentiate them from ordinary liquids. We use the term “ionic liquid (IL)”
for these substances in this article [1].
One of the earliest truly room temperature-ILs was ethylammonium nitrate (C2H5)NH3NO3 (m.p.
12 ◦C), reported in 1914 by Paul Walden [2]. However, no active research on ILs was carried out until
late in the 20th century. Recently, ILs have started to attract attention as “designer solvents” because
they have various functions through adjusting the physical properties of the cationic and anionic
species of their constituents [3]. Many commercial applications have already been considered.
In the field of pharmaceutical sciences, IL forms of many pharmaceuticals have been investigated.
Combining a pharmaceutically active cation with a pharmaceutically active anion leads to a dual active
IL, in which the actions of the two drugs are combined [4,5]. ILs can extract specific active compounds
from plants for pharmaceutical, nutritional, and cosmetic applications, such as the antimalarial drug
artemisinin from the plant Artemisia annua [6]. Improvement of the gastrointestinal absorption of drugs
by IL conversion [7–9] and improvement of the solubility of poorly soluble drugs using ILs [10,11] have
been actively studied. Regarding enhancement of the percutaneous absorption of drugs examined in
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his study, it has been reported that skin permeation of drugs was enhanced by IL formation [12–17] and
IL micelle formation as well [18,19]. However, these studies using ILs focused only on improvement
of the skin permeability of lipophilic drugs with relatively high skin permeation properties [20–22],
and few studies have been done to increase the skin permeation of hydrophilic drugs with low skin
permeability. Furthermore, these ILs aimed at improving skin permeability, but there have been no
reports that the permeability of a plurality of constituent drugs has been improved.
L-ascorbic acid (VC) (acidic compound; M.W. 176.12; log (Kow − 2.15)) (I in Figure 1) is known
as a representative compound with low skin permeability due to its high polarity. Several methods
have already been studied for promoting the skin permeability of VC [23,24]. However, despite its
low skin permeability, VC is still widely used as an active ingredient for quasi-drugs, a category
regulated in Japan for functional cosmetics, with the expectation of whitening and antioxidant effects.
Another water-soluble vitamin, pyridoxine (VB6) (basic compound; M.W. 169.18; log (Kow − 0.77))
(II in Figure 1), is also used in quasi-drugs with the expectation of a moisturizing effect. VB6 also has
low skin permeability. Both of these compounds are expected to have higher efficacy if their skin
permeability is improved and are also expected to lead to reduced dosages.
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Figure 1. Chemical structure of L-ascorbic acid (VC) (I) and pyridoxine (VB6) without (II) and with 
intramolecular hydrogen bond (II’). 
In this study, we selected VC and VB6, which are an anion and a cation, respectively, and 
prepare a mixture using the solvent evaporation method. Then, the changes in physicochemical 
properties and intermolecular interactions for both active ingredients in the mixture were examined 
to determine whether the mixture was an IL or not. Finally, the effect of IL conversion on the skin 
permeability of both active ingredients was evaluated. 
2. Materials and Methods 
2.1. Materials 
VC, diethyl sebacate, and 1,3-butanediol were purchased from Tokyo Chemical Industry Co., 
Ltd. (Tokyo, Japan), and the base form of pyridoxine (VB6) and dimethyl sulfoxide-d6 (DMSO-d6) 
were purchased from Sigma Aldrich (St. Louis, MO, USA). 
2.2. Preparation of VC-VB6 IL 
An IL containing VC and VB6 was prepared using a solvent evaporation method. After 
dissolving an equal molar of VC (1.76 g) and VB6 (1.69 g) in ethanol (200 mL), the solvent was 
distilled off using an evaporator at 40 °C for 1 h to obtain a slightly yellow and highly viscous 
substance containing VC and VB6 as constituents. Hereinafter, this will be referred to as a “highly 
viscous substance” until IL conversion is confirmed. 
Figure 1. Chemical structure of L-ascorbic acid ( C) (I) and pyridoxine (VB6) without (II) and with
intramolecular hydrogen bond (II’).
In this study, we selected VC and VB6, which are an anion and a cation, respectively, and prepare
a mixture using the solvent evaporation method. Then, the changes in physicochemical properties and
intermolecular interactions for both active ingredients in the mixture were examined to determine
whether the mixture was an IL or not. Finally, the effect of IL conversion on the skin permeability of
both active ingredients was evaluated.
2. Materials and Methods
2.1. Materials
VC, diethyl sebacate, and 1,3-butanediol were purchased from Tokyo Chemical Industry Co., Ltd.
(Tokyo, Japan), and the base form of pyridoxine (VB6) and dimethyl sulfoxide-d6 (DMSO-d6) were
purchased from Sigma Aldrich (St. Louis, MO, USA).
2.2. Preparation of VC-VB6 IL
An IL containing VC and VB6 was prepared using a solvent evaporation method. After dissolving
an equal molar of VC (1.76 g) and VB6 (1.69 g) n ethanol (200 mL), the solvent was distilled off using
an evaporator at 40 ◦C for 1 h to obtain a slightly yellow and highly viscous substance containing VC
and VB6 as constituents. Hereinafter, this will be referred to as a “highly viscous substance” until IL
conversion is confirmed.
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2.3. Differential Thermal Analysis
The melting point of the highly viscous substance was measured using a differential scanning
calorimeter (DSC) (Thermo Plus EVO/DS C8230, Rigaku Corporation, Akishima, Tokyo, Japan).
In addition to this highly viscous substance, VC alone, VB6 alone, and their physical mixture (by mixing
using a mortar) were also measured for comparison. Each sample was put in an aluminum sample
container (Rigaku Corporation), and the thermal behavior was measured from 10 ◦C to 300 ◦C at a
heating rate of 10 ◦C/min.
2.4. X-ray Diffraction Measurement
The crystallinity of the highly viscous substance was evaluated using an X-ray diffractometer
(XRD) (Mini Flex II, Rigaku Corporation). VC alone, VB6 alone, and the physical mixture were used for
comparison. Each sample was placed on a glass sample plate (Rigaku Corporation), and the operation
range and scanning speed were set to 2.0–60.0◦ and 3◦/min, respectively.
2.5. Nuclear Magnetic Resonance Measurement
The intermolecular and intramolecular interactions between VC and VB6 in the highly viscous
substance were evaluated using a nuclear magnetic resonance (NMR) apparatus (Varian 400-NMR,
Agilent Technologies, Santa Clara, CA, USA). VC alone, VB6 alone, and their physical mixture were
also used for comparison. DMSO-d6 was used as a solvent, and the weight of each sample was adjusted
to 10 mg.
2.6. Solubility Measurement in Diethyl Sebacate and 1,3-Butanediol
The highly viscous substance was dropped into diethyl sebacate and 1,3-butanediol and stored at
32 ◦C for over 72 h to prepare highly viscous substance-saturated 1,3-butanediol and diethyl sebacate,
respectively. Then, the solubilities of VC and VB6 in each solvent were measured by high-performance
liquid chromatography (HPLC).
2.7. Determination of VC and VB6
Each sample containing VC and VB6 was mixed with an equal volume of acetonitrile and
centrifuged at 21,500× g, 4 ◦C for 10 min using a centrifuge (Himac CT15RE, Koki Holdings Co.,
Ltd., Tokyo, Japan). Then, 20 µL of the supernatant was injected into an HPLC. The HPLC system
consisted of a pump (LC-20AD, Shimadzu Corp., Kyoto, Japan), an injector (SIL-20AC, Shimadzu
Corp.), a column oven (CTO-20AC, Shimadzu Corp.), a UV-VIS detector (SPD-M20A, Shimadzu
Corp.), a system controller (CBM-20AC, Shimadzu Corp.). An NH2 column (Inertsil® NH2, 5 µm,
4.6 × 150 mm, GL Science, Tokyo, Japan) was used and analyzed with an analytical data processing
system (LCsolution, Shimadzu Corp.). Mobile phase and wavelength for detection for VC and VB6
were acetonitrile:50 mM phosphoric acid aq. = 20:80 and 50:50 and UV 245 nm and 290 nm, respectively.
2.8. Animals
Male hairless rats (WBN/Ila-Ht), weighing about 180 g and 8 weeks old were obtained from
Ishikawa Laboratory Animals (Fukaya, Saitama, Japan). The rats were housed in a room at 25 ± 2 ◦C
and the light turned on and off every 12 h. The rats had ad libitum access to water and food (obtained
from Oriental Yeast Co., Ltd., Tokyo, Japan). All animal experiments and feeding methods were
approved by the Institutional Animal Care and Use Committee of Josai University (Sakado, Saitama,
Japan, No. JU18003, 3 April 2018).
2.9. In Vitro Skin Permeation Experiment
A hairless rat was anesthetized with an intraperitoneal injection of three types of anesthesia
(medetomidine hydrochloride; 0.15 mg/kg, midazolam; 2.0 mg/kg and butorphanol tartrate; 2.5 mg/kg)
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and killed by cervical dislocation. Then, full-thickness abdominal skin was excised from the body.
The subcutaneous fat and blood vessels were carefully removed on the dermis side from the excised
skin, and the skin was mounted on a vertical diffusion cell (cell volume: 6.0 mL, effective permeation
area: 1.77 cm2) [25]. To prevent oxidative degradation of VC and to hydrate the skin, 1.0 and
6.0 mL of phosphate buffered saline (PBS) containing 0.3% homocysteine were applied to the stratum
corneum and dermis side, respectively, for 1 h before the skin permeation experiment. After hydration,
the PBS containing homocysteine on the stratum corneum was removed, and 1.0 mL of IL solution in
1,3-butanediol at a concentration of 200, 500, or 1000 mM was applied to the stratum corneum side
(176.12 mg VC/mL and 169.18 mg VB6/mL at 1000 mM). The same volume of the physical mixture of
VC and VB6 at a concentration of 200 or 1000 mM in 1,3-butanediol was also tested for comparison.
These samples were suspended in 1,3-butanediol because their solubilities in 1,3-butanediol were
much lower than their IL sample (see details in Results).
During the experiment, the cell was maintained at 32 ◦C and the inside of the receiver cell was
constantly stirred magnetically with a star head type stirrer. An aliquot (0.5 mL) was sampled from the
receptor compartment over time, and the same amount of PBS was replenished to the dermis each
time. VC and VB6 concentrations in the sample solution were measured by HPLC. All in vitro skin
permeation experiment was performed with 3 to 4 repeats.
3. Results
3.1. Effect of Ionic Liquid on the Melting Points of VC and VB6
Figure 2 shows a DSC thermogram for VC and VB6. Four samples (original powder of VC and VB6,
their physical mixture, and a highly viscous substance prepared in this study) were tested. The original
powders of VC and VB6 showed endothermic peaks at 190.1 ◦C and 159.8 ◦C, respectively (Figure 2a,b).
These were due to their melting. On the other hand, no clear melting points were found from room
temperature to over 200 ◦C and a broad exothermic peak was observed at about 165 ◦C for the physical
mixture and the highly viscous substance (Figure 2c,d).
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Figure 2. DSC thermograms of L-ascorbic acid (VC) (a), pyridoxine (VB6) (b), physical mixture of VC
and VB6 (c), and their ionic liquid (IL) (d).
3.2. Effect of Ionic Liquid on the Crystalline Properties of VC and VB6
Figure 3 shows the powder X-ray diffraction patterns for VC and VB6. Original powder of VC
(a) and VB6 (b), their physical mixture (c), and the highly viscous substance (d) were also tested
as in Figure 2. Seve al diffraction peaks were found in the original powders of VC and VB6, those
derived from thei crystal structur s as shown in Figure 3a,b. Similar kinds of peaks were observed
in the physical mixture of VC and VB6 (Figure 3c). Although the diffraction pattern in Figure 3c
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for the physical mixture was close to that in Figure 3b for VB6 rather than that in Figure 3a for VC
and generally lower peaks compared with that for VC, no clear reason was estimated. On the other
hand, no diffraction peaks were observed in the highly viscous substance (Figure 3d), suggesting that
amorphization has been confirmed. It was also suggested that there was some interaction between VC
and VB6 in the highly viscous substance prepared by solvent evaporation, which were different from
the physical mixture. To clarify the difference between the physical mixture and the highly viscous
substance, 1H NMR was then used.
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3.3. Effect of Ionic Liquid on Intermolecular Interactions between VC and VB6
Possibilities of the intermolecular interaction between VC and VB6 as well as and the intramolecular
interaction in th e compou ds were evaluated for the physical mixture the highly viscous substanc
using NMR. Figure 4 shows the 1H NMR spectra obtained by NMR measurements. Again, the original
powder of VC and VB6, their physical mixt , and the highly viscous substance were tested as in
Figures 2 and 3. We paid attent on only to the signal that appeared at around 5 ppm for VB6. T is triplet
signal at 5 ppm disapp ar d with the addition of deuterium oxide (D2O). Thus, his signal can be
ssigned at a hydroxyl roton making an intramolecular hydrogen bond (Figure 4b). A similar peak
profile derived from a hydrogen bond was confirmed in the physical mixture (Figure 4c), although the
sign l was observe as a broad triplet, as shown in Figu e 4c. Howev r, such a peak profile disappeare
in the highly viscous substance (F gure 4d). It was considered from the above data that the highly
viscous substance for VC-VB6 prepared in this study has a diff rent intramolecular interaction fr m
the physical mixing treatment. Results shown in Figures 3 and 4 indicated that the highly viscous
substance must be a IL. Hereinafter, this substance is referred to as IL. The p esent x eriments us
1H NMR spectroscopy suggested that the LC conversion eliminated intramolecular hydrogen bonds
found in VB6. The pre med structural formula i I ’ (see Figure 1) for the original powder of VB6
and the physical mixture of VC-VB6. VB6 had a hydrogen bo d in th molecule, but it was eliminated
when pr paring the IL form.
3.4. The Solubility of VC and VB6 in Diethyl Sebacate and 1,3-Butanediol
Figure 5a,b show the solubility of VC and VB6 in diethyl sebacate and 1,3-butanediol, respectively.
The physical mixture and IL for VC and VB6 were used as samples. The solubility of both VC and
VB6 from their physical mixture was very low both in diethyl sebacate and 1,3-butanediol. This was
as expected because these original compounds are both highly hydrophilic. The solubility of these
compounds in 1,3-butanediol was higher than that in diethyl sebacate. This is due to 1,3-butanediol
being more highly hydrophilic than diethyl sebacate. On the other hand, the IL form was markedly
soluble both in diethyl sebacate and 1,3-butanediol. The solubility for VC and VB6 in diethyl sebacate
was calculated as 41.9–45.2%, and that for VC and VB6 in 1,3-butanediol was 41.4–45.2%. The weight
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ratio (or molar ratio) of VC and VB6 in the LC form was estimated to be almost 1:1, because the
molecular weights of these compounds is similar to each other. Determination of the solubility of the IL
in diethyl sebacate was a little difficult because IL was not fully miscible with the solvent. Then, VC and
VB6 concentrations in the diethyl sebacate-absorbed IL phase were determined. As explained above,
the present IL showed much higher VC and VB6 solubility in diethyl sebacate as in 1,3-butanediol.
Almost 90 g of IL dissolved in 100 g of solution.Pharmaceutics 2020, 12, x 6 of 10 
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Figure 5. The solubility (%) of VC-VB6 from the IL and physical mixture of VC and VB6 in diethyl
sebacate (a) or 1,3-butanediol (b).
3.5. Skin Permeation of VC and VB6 from 1,3-Butanediol
Finally, skin permeation of VC and VB6 was determined from the IL form presently using the
original powders of VC and VB6. Full-thickness hairless rat abdominal skin was used in this experiment.
Figure 6a and b show the cumulative amount of VC and VB6, respectively, permeated through rat skin
from the prepared IL in 1,3-butanediol at a concentration of 200, 500, or 1000 mM. The IL solution
(1.0 mL) was applied to 1.77 cm2 of skin, thus the applied dose of VC and VB6 was calculated to be
99.5 and 95.6 mg/cm2, respectively, in the case of the 1000 mM application. The physical mixture of VC
and VB6 in 1,3-butanediol was used for comparison. Due to their low solubilities in 1,3-butanediol,
the same amount of VC and VB6 compared to 200 mM and 1000 mM IL solutions (35.22 mg VC/mL
and 33.84 VB6/mL at 200 mM; 176.12 mg VC/mL and 169.18 mg VB6/mL at 1000 mM) was applied as
Pharmaceutics 2020, 12, 427 7 of 10
suspension. The solubility of VC and VB6 in 1.3-butanediol is 1.9% and 2.9%, as shown in Figure 5,
which corresponded to about 108 and 171 mM, respectively. Thus, the physical mixture samples were
suspended in 1,3-butanediol even when applied at 200 mM. All skin permeation profiles showed
typical lag time and following pseudo-steady state flux. The time course after the lag time-period
showed a slightly convex profile, although the reason was unclear.
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The IL group showed a much higher cumulative amount of both VC and VB6 permeated through the 
skin than those from their physical mixture compared with each application of 200 and 1000 mM. 
The cumulative amount of skin permeation from the IL form increased in an application 
concentration-dependent manner, whereas that from the physical mixture did not. This was due to 
the saturated amount being applied both for the 200 and 1000 mM physical mixture [25]. 
Degradation of vitamin C in the donor and receiver compartments was also investigated after 
finishing the permeation study. No degradation was occurred during the experiment (data not 
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Figure 6. Time course of the cumulative amount of VC (a) and VB6 (b) permeated through hairless rat
full-thickness skin from their 1,3-butanediol solution and the relationship between applied concentration
and the calculated flux of VC (c) and VB6 (d) from this figure a and b. Symbol: # 200 mM IL, 3 500 mM
IL,  1000 mM IL, • 200 mM physical mixture (35.22 mg VC/mL and 33.84 VB6/mL),  1000 mM physical
mixture (176.12 mg VC/mL and 169.18 mg VB6/mL). Each value shows the mean ± S.D. (n = 3–4).
Figure 6c and d show the relationship between the steady-state skin permeation rate calculated from
data shown in Figure 6a and b and the applied concentration of VC and VB6 in 1,3-butanediol. The IL
group showed a much higher cumulative amount of both VC and VB6 permeated through the skin than
those from their physical mixture compared with each application of 200 and 1000 mM. The cumulative
amount of skin permeation from the IL form increased in an application concentration-dependent
manner, whereas that from the physical mixture did not. This was due to the saturated amount being
applied both for the 200 and 1000 mM physical mixture [25]. Degradation of vitamin C in the donor
and receiver compartments was also investigated after finishing the permeation study. No degradation
was occurred during the experiment (data not shown).
4. Discussion
An IL is a kind of eutectic mixture and can be considered as a low melting molten salt. A eutectic
mixture with a low melting point is formed when a powder composed of two or more components
is mixed at a certain ratio. ILs are made of a range of compounds composed of anions and cations.
Several ILs containing VC have been reported previously. Niemczak et al. prepared ILs of VC anion
with dimethyldioctylammonium and didecyldimethylammonim cations [25]. They confirmed the
strong influence of the cations on the stability of VC in air as well as in aqueous solutions. Additionally,
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the synthesized VC IL exhibited very good antibacterial and antifungal properties against different
microorganisms, including pathogens.
In the present study, we planned to use an IL composed of both VC and VB6 to increase
the skin permeation of both compounds. Among ILs reported thus far, cation moieties such as
imidazolium, ammonium, and pyridinium type are well utilized. This is because these materials
are relatively inexpensive and easily available. Such quaternary salts are usually prepared from
a nitrogen-containing compound and an alkyl halide and are mixed with an appropriate anion to
synthesize such ILs. On the other hand, in the present study, the cation part was VB6 and the anion was
VC. An IL of VC-VB6 was prepared by dissolving both powders in ethanol and evaporating the solvent.
First, the physical properties of the highly viscous substance prepared in this study and the reason
why we judged this substance to be an IL will be discussed. Removal of ethanol from the VC and
VB6 ethanol solutions resulted in a slightly yellowish and highly viscous substance. DSC and X-ray
diffraction of this substance were measured. As a result, the highly viscous substance did not show a
clear melting point (Figure 2d) and, unlike the physical mixture, did not show crystallinity (Figure 3c,d).
The DSC thermogram of the physical mixture (Figure 2c) was almost the same as that of IL (Figure 2d).
It can be expected that VC and VB6 may react to become an IL when the temperature applied to the
sample increased during the DSC measurement. Furthermore, the physical mixture itself may contain
IL because both compounds may react during mixing in a mortar. However, the fact that the physical
mixture was not entire IL was also evident from the fact that it has a diffraction pattern (Figure 3c).
Next, an experiment using 1H NMR spectroscopy was performed. As a result, it was suggested
that the intramolecular hydrogen bond seen in VB6 disappeared in the LC conversion, although this
phenomenon was not observed in the physical mixture. The presumed structure of VB6 is II’ shown in
Figure 1 in free VB6 or VB6 in the physical mixture, and there is a hydrogen bond in the molecule, but
VB6 in the IL seemed to exist as II without a hydrogen bond.
Lipid-soluble diethyl sebacate and water-soluble 1,3-butanediol were used as solvents in the
solubility test. The logarithmic water–octanol partition coefficient, log Kow, of these solvents is 3.07
and –0.23, respectively. IL dissolved in a small amount of 1,3-butanediol, and the solubility for
both VC and VB6 exceeded 40%. It was surprising that the combined solubility of VC and VB6
in 1,3-butanediol was about 87% (weight ratio). The solubility of VC in 1,3-butanediol was 41.9%,
which was much higher than the advertised value (ca 25%) for the highest concentration of VC using
polyethylene glycol from the patent information [26]. On the other hand, the IL prepared in this study
was not freely soluble in diethyl sebacate. That is, when diethyl sebacate and the IL were mixed,
a diethyl sebacate phase containing the IL and a diethyl sebacate phase containing no IL were formed.
Therefore, the concentration of VC and VB6 in the diethyl sebacate phase containing IL was measured.
As a result, the VC and VB6 solubility in diethyl sebacate was almost the same as that in 1,3-butanediol.
The solubility of VC and VB6 from the physical mixture in 1,3-butanediol was low (1.9% and 2.9%,
respectively).
Although the IL containing VC and VB6 prepared became more lipophilic than the original
powders of VC and VB6, the log Kow was thought to be about 0. More detailed log Kow and solubility
parameters of the IL should be able to be estimated using more solvents.
The solubility of the present IL showed higher solubility in the two solvents, confirming that the
IL conversion increased the hydrophobicity compared with VC and VB6 alone. In addition, the amount
of VC and VB6 that permeated through the skin was significantly enhanced by IL conversion compared
with either drug alone or the physical mixture. When the IL was applied, the amount of skin permeation
increased in a concentration- or thermodynamic activity-dependent manner (Figure 6). The relationship
between the skin permeation rate (Fick’s law of diffusion) and concentration (thermodynamic activity)
of applied drugs was clearly explained more than 50 years ago [27]. It was considered from these
results that the permeation rate of these vitamins through the skin was increased by increasing the
solubility of VC and VB6 in 1,3-butanediol by the present IL formulation.
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In general, the IL: (1) Was non-volatile having almost no vapor pressure, (2) non-combustible
and non-flammable, (3) had high thermal stability and did not decompose even at high temperatures
of 300 ◦C or more, (4) has solvent-like properties and effectively dissolved various salts and organic
compounds [28]. Therefore, the present IL is a candidate for a stable formulation of VC even in water.
5. Conclusions
IT this study, an IL form containing VC and VB6 components was prepared successfully. It was
found that the IL compound arbitrarily mixed with 1,3-butanediol and dissolved at an extremely high
concentration. Furthermore, it was considered that the present IL formation may be useful as a method
for increasing the concentration and enhancing the skin permeation rates of both VC and VB6.
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